Unadjusted Cox HRs for deterioration in lung function over time according to each baseline characteristic
| HR (95% CI) | p Value | |
| Demographics | ||
| Age (as continuous variable, per year) | 1.02 (0.99 to 1.05) | 0.142 |
| Men* | 1.96 (0.90 to 4.26) | 0.089 |
| History of smoking* | 0.70 (0.27 to 1.79) | 0.451 |
| Systemic sclerosis | ||
| Diffuse form of SSc* | 2.56 (1.35 to 4.76) | 0.011 |
| Duration of disease (as continuous variable, per year) | 1.00 (0.97 to 1.03) | 0.843 |
| Lung disease | ||
| Presence of ILD* | 3.52 (1.75 to 7.08) | 0.001 |
| Tlco (as continuous variable, per %†) | 0.96 (0.94 to 0.98) | <0.001 |
| FVC (as continuous variable, per %†) | 0.98 (0.96 to 0.99) | 0.005 |
| Presence of pulmonary hypertension* | 1.32 (0.40 to 4.28) | 0.651 |
| Treatment | ||
| Immunosuppressive treatment* | 2.32 (1.15 to 4.67) | 0.024 |
| Exhaled nitric oxide | ||
| FEno0.05 (as continuous variable, per ppb) | 1.02 (1.00 to 1.03) | 0.061 |
| CAno (as continuous variable, per ppb) | 1.06 (1.03 to 1.09) | <0.001 |
| SSc patients with CAno >5.3 ppb* | 6.80 (2.84 to 16.26) | <0.001 |
| J′awno (as continuous variable, ml/min) | 1.00 (0.99 to 1.01) | 0.762 |
↵* As categorical variable.
↵† Proportion of predicted value.
CAno, alveolar concentration of nitric oxide; Tlco, carbon monoxide transfer factor; FEno0.05, fractioned exhaled nitric oxide at 50 ml/min of outflow; FVC, forced vital capacity; ILD, interstitial lung disease; J′awno, conducting airways nitric oxide output; PAP, pulmonary artery pressure assessed by echocardiogrphy; ppb, parts per billion; SSc, systemic sclerosis.